How is Jiahui’s First Ever CAR-T Patient Doing One Year Later?
Jiahui Health 嘉会医疗
Jiahui Health is an international healthcare provider, and the first foreign-funded healthcare ecosystem in China.
Recently, we received a set of special photos. These photos are from Lyn She-Wu, an effervescent mother of three, recording the wonderful moments of her diving adventure trip with her family this summer. With such lively photos, it’s hard to believe she was in a hospital bed battling cancer just a year ago.?
Lyn is the first lymphoma patient to receive CAR-T treatment at Jiahui, and the first foreign lymphoma patient in China to opt for Axicabtagene Ciloleucel injection CAR-T therapy. On September 13, 2023, she was successfully discharged from Shanghai Jiahui International Hospital 3 weeks after infusion of CAR-T cells, which is one year ago from today.?
My time diving in the clear waters of Palau proves that life after cancer recovery does not mean missing out on exciting experiences. On the contrary, it shows that with proper preparation and support, one can still pursue adventures and enjoy the wonders of life after cancer recovery. —Lyn She-Wu
This has not been an easy accomplishment, but we are proud of the progress we've made.?Join us as we reflect on the remarkable journey of Jiahui Health's CAR-T development.
First, you may be wondering, what is CAR-T?
Chimeric antigen receptor (CAR)-T therapy utilizes the patient’s own immune cells, which are genetically modified to enhance their anti-cancer capabilities. Clinical data has shown significantly higher efficacy in refractory or relapsed cases that is impossible with traditional treatments.
T cells extracted from the patient are modified through genetic engineering by pharmaceutical companies to boost their anti- cancer effects. These modified T cells are reintroduced into the patient’s body, where they target and destroy malignant cells, and enhance patient’s immune to eliminate cancer cells.
What is the CAR-T therapy process?
The treatment process involves: Patient’s Assessment, T-cell Collection, Engineering, Expansion, CAR-T cell infusion and Monitoring. Post CAR-T therapy, the patient will be followed closely to ensure the effectiveness of the therapy.
Who can have CAR-T therapy?
CAR-T therapy is suitable for blood cancer. In China, the approved indications for CAR-T therapy include lymphoma, multiple myeloma, and leukemia.
Recent Milestones
September?13 2023 First CAR-T?Lymphoma Patient?Discharged
September?14 2023 Vital Partnerships
Representatives from Jiahui International Hospital and IASO signed a strategic cooperation agreement on behalf of both parties.?The collaboration aimed to integrate strategic efforts, combining business development and technological strengths to establish an internationally standardized cell immunotherapy center using CAR-T technology.
Together, they delved into innovative models like insurance payment structures around CAR-T, fostering the comprehensive application and sustainable growth of the CAR-T international diagnosis and treatment platform. This partnership sought to extend international innovative therapies to a broader spectrum of cancer patients globally, ensuring enhanced benefits for individuals both domestically and overseas.
End of 2023 First CAR-T Myeloma Patient Discharged
The first myeloma patient from New Zealand who received CAR-T cell immunotherapy at Shanghai Jiahui International Hospital was successfully discharged within two weeks after completing treatment.
“My entire treatment journey at Jiahui has been smooth throughout. I've had really good support from the medical team – from my doctors through to the nursing team. It's been a good experience,” the patient shared.
April 2024 Convenient Payment Options?
Jiahui International Cancer Center (JICC) offers convenient payment options, which includes supporting payment methods from major outpatient medical insurance providers and cross-regional outpatient direct payments. We partner with 50+ commercial insurance providers.?
As one of the medical institutions in Shanghai to offer CAR-T therapy, Jiahui International Hospital has been included in the Huhuibao (沪惠保), a regional health?insurance?benefit in Shanghai, as a designated hospital for CAR-T therapy.?
The cost of CAR-T therapy is predominantly made up of drug expenses and non-drug expenses. The total treatment cost for this therapy in China is significantly lower than in the United States and in European countries. Payment for the CAR-T therapy program at JICC can be settled through commercial insurance or self-pay.
May 23 2024 International Symposium on CAR-T Therapy
On May 23, 2024, Shanghai Jiahui International Hospital, Jiahui Medical Research and Education Group (J-MED) and its NEJM (New England Journal of Medicine) jointly held the "International Symposium on CAR-T Therapy for Blood Cancer".?
Many other industry leaders from the United States, Singapore, Malaysia, Russia, and China participated in the seminar and shared their views, focusing on innovative CAR-T therapies for hematological tumors, and conducting detailed discussions on topics such as oncology clinical trial design, the latest advancements in CAR-T therapies for hematological tumors, and the progress of CAR-T its application in China.
May 2024 Five Approved CAR-T Products Introduced at Jiahui
As of May 2024, Shanghai Jiahui International Hospital has successively reached important cooperation with Fosun Kite, IASO BioTherapeutics, JW Therapeutics, China Heading Medical Group, and HeYuan Biotechnology in the introduction of CAR-T drugs and academic exchanges. Since then, five CAR-T drugs approved for commercialization in China (Axicabtagene Ciloleucel?Injection, Rebecel Injection, Ibrexafungerp Injection, Zevokacabtagene Injection, and Naxicabtagene Injection) have been successfully introduced in Jiahui International Hospital, providing more treatment options for cancer patients at home and abroad.
September 2024 Multiple Patients Discharged With Complete Remission?Achieved
As of September 2024, Shanghai Jiahui International Hospital has successfully completed CAR-T treatment for patients from Russia, Singapore, New Zealand, China, and other countries. So far, patients who have been discharged from Jiahui International Hospital for over three months and have undergone evaluation have achieved complete remission, indicating promising results.
Looking ahead, Jiahui is committed to its mission of fostering the CAR-T international diagnosis and treatment platform. Under the leadership of?Dr. Vicky Lee, the CAR-T Multidisciplinary Team (MDT) team at Jiahui International Cancer Center is pioneering innovative clinical practices and technologies, offering new hope and treatments to patients with blood cancers.?
JICC will continue to share clinical experiences, exchanging academic progress, and providing blood cancer education to industry healthcare professionals.
Jiahui International Cancer Center
Jiahui International Cancer Center (JICC), affiliated with Shanghai Jiahui International Hospital, has a close strategic collaboration with Massachusetts General Hospital and its cancer center. Jiahui International Cancer Center represents the cutting edge of international oncology, providing patients over the age of 14 with fast, comprehensive, international-standard diagnosis and treatment.? Jiahui International Cancer provides advanced diagnosis and treatment methods, meticulous and holistic care, thorough communication, an approach that places the needs of you and your family at the core, comprehensive support, a safe and comfortable environment, and professional follow-up care.
CAR-T therapy, or chimeric antigen receptor T-cell therapy, is a major breakthrough in personalized cellular immunotherapy for cancer. The process involves the collection of the patient's T-cells, after which in vitro genetic engineering modifications of T-cells are made to enhance the T-cells' ability to specifically recognize cancers. These modified T-cells (i.e., CAR-T cells) are then infused back to the patient. The treatment enables the accurate killing of cancer cells and the formation of memory T-cells that fight the cancer in the long term and ensure a more sustainable remission.
Currently, CAR-T therapy has been approved in China for the treatment of lymphoma and multiple myeloma. CAR-T therapy is individualized in nature and involves many key aspects such as patient screening, bridging therapy, adverse reaction management, and long-term follow-ups.Jiahui’s CAR-T multidisciplinary treatment team, led by Dr. Vicky LEE, Director of the Jiahui International Cancer Center (JICC) and Chief of Medical Oncology at JICC, has been doing a series of explorations in the clinical practice of novel concepts and technologies, aiming to bring hope and new treatments to more patients with blood cancers.
#shanghai #chinahospital #cancertreatment #cartcell #immunotherapy #lymphoma #leukemia #myeloma
Digital cancer pathologist; cybersecurity architect.
2 个月Attitude and cancer survival. Many cancers have become a chronic illness and are survivable for a lifetime, We survive cancer through science, early detection and real health insurance. Attitudes doesn’t have anything to do with cancer survival. Patient's experience and insights should be respected including who decide not to have further treatments Cancer is a difficult disease, but with right treatment and support, many can live a long and healthy life.